{"id":"https://openalex.org/W2051028531","doi":"https://doi.org/10.1097/01.mib.0000436951.80898.6d","title":"Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis","display_name":"Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis","alternate_titles":[],"publication_year":2013,"publication_date":"2013-11-26","ids":{"openalex":"https://openalex.org/W2051028531","doi":"https://doi.org/10.1097/01.mib.0000436951.80898.6d","mag":"2051028531","pmid":"https://pubmed.ncbi.nlm.nih.gov/24280879"},"language":"en","primary_location":{"id":"doi:10.1097/01.mib.0000436951.80898.6d","doi":"https://doi.org/10.1097/01.mib.0000436951.80898.6d","is_oa":false,"landing_page_url":"https://doi.org/10.1097/01.mib.0000436951.80898.6d","pdf_url":null,"source":{"id":"https://openalex.org/S45123234","display_name":"Inflammatory Bowel Diseases","issn_l":"1078-0998","issn":["1078-0998","1536-4844"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Inflammatory Bowel Diseases","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2051028531"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001151390","display_name":"Sorcha O\u2019Meara","orcid":"https://orcid.org/0000-0003-2502-5450","observed_orcids":["https://orcid.org/0000-0003-2502-5450"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sorcha O\u2019Meara","raw_affiliation_strings":["Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112013489","display_name":"Kavinderjit S. Nanda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kavinderjit S. Nanda","raw_affiliation_strings":["Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5062491410","display_name":"Alan C. Moss","orcid":"https://orcid.org/0000-0003-0179-5477","observed_orcids":["https://orcid.org/0000-0003-0179-5477","https://orcid.org/0009-0007-0879-3884"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alan C. Moss","raw_affiliation_strings":["Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3862,"currency":"USD","value_usd":3862},"apc_paid":null,"fwci":2.0546,"has_fulltext":false,"cited_by_count":182,"citation_normalized_percentile":{"value":0.88858195,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":95,"max":100},"biblio":{"volume":"20","issue":"1","first_page":"1","last_page":"6"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-infliximab-antibodies","display_name":"anti-infliximab antibodies","score":0.7900000214576721},{"id":"https://openalex.org/keywords/infusion-related-reactions","display_name":"infusion reactions","score":0.8730000257492065}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9108614921569824},{"id":"https://openalex.org/C82789193","wikidata":"https://www.wikidata.org/wiki/Q2142611","display_name":"Relative risk","level":3,"score":0.7177263498306274},{"id":"https://openalex.org/C2778260677","wikidata":"https://www.wikidata.org/wiki/Q917447","display_name":"Inflammatory bowel disease","level":3,"score":0.6623314023017883},{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.6362330317497253},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5858915448188782},{"id":"https://openalex.org/C82605166","wikidata":"https://www.wikidata.org/wiki/Q967190","display_name":"Funnel plot","level":4,"score":0.5579422116279602},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.5550956130027771},{"id":"https://openalex.org/C2780439572","wikidata":"https://www.wikidata.org/wiki/Q919364","display_name":"Publication bias","level":3,"score":0.5146280527114868},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.5057775974273682},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4375237822532654},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.3531399369239807}],"mesh":[{"descriptor_ui":"D000069285","descriptor_name":"Infliximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000888","descriptor_name":"Antibodies, Anti-Idiotypic","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D000894","descriptor_name":"Anti-Inflammatory Agents, Non-Steroidal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004342","descriptor_name":"Drug Hypersensitivity","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015212","descriptor_name":"Inflammatory Bowel Diseases","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D015212","descriptor_name":"Inflammatory Bowel Diseases","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/01.mib.0000436951.80898.6d","doi":"https://doi.org/10.1097/01.mib.0000436951.80898.6d","is_oa":false,"landing_page_url":"https://doi.org/10.1097/01.mib.0000436951.80898.6d","pdf_url":null,"source":{"id":"https://openalex.org/S45123234","display_name":"Inflammatory Bowel Diseases","issn_l":"1078-0998","issn":["1078-0998","1536-4844"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Inflammatory Bowel Diseases","raw_type":"journal-article"},{"id":"pmid:24280879","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24280879","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Inflammatory bowel diseases","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[{"id":"https://openalex.org/G4397779030","display_name":"Purinergic Pathways in Crohn's Disease","funder_award_id":"K23DK084338","funder_id":"https://openalex.org/F4320337357","funder_display_name":"National Institute of Diabetes and Digestive and Kidney Diseases"}],"funders":[{"id":"https://openalex.org/F4320337357","display_name":"National Institute of Diabetes and Digestive and Kidney Diseases","ror":"https://ror.org/00adh9b73"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":37,"referenced_works":["https://openalex.org/W1576173198","https://openalex.org/W1964924603","https://openalex.org/W1968655366","https://openalex.org/W1971331540","https://openalex.org/W1975033484","https://openalex.org/W1976821928","https://openalex.org/W1979423827","https://openalex.org/W1980254110","https://openalex.org/W1981680557","https://openalex.org/W1997999969","https://openalex.org/W2003314961","https://openalex.org/W2003904406","https://openalex.org/W2008629972","https://openalex.org/W2017295150","https://openalex.org/W2023078169","https://openalex.org/W2026116536","https://openalex.org/W2065795543","https://openalex.org/W2069644264","https://openalex.org/W2072711218","https://openalex.org/W2086415546","https://openalex.org/W2086767087","https://openalex.org/W2087663450","https://openalex.org/W2090393370","https://openalex.org/W2116034364","https://openalex.org/W2117212747","https://openalex.org/W2118559127","https://openalex.org/W2126930838","https://openalex.org/W2134803931","https://openalex.org/W2135400982","https://openalex.org/W2136580860","https://openalex.org/W2141139109","https://openalex.org/W2157823046","https://openalex.org/W2159143303","https://openalex.org/W2171202562","https://openalex.org/W2171297959","https://openalex.org/W2171341132","https://openalex.org/W2321453230"],"related_works":["https://openalex.org/W2002991484","https://openalex.org/W2144974498","https://openalex.org/W1546652561","https://openalex.org/W2925128160","https://openalex.org/W2106072130","https://openalex.org/W2064527996","https://openalex.org/W2969770936","https://openalex.org/W2003314961","https://openalex.org/W1965678072","https://openalex.org/W4296618051"],"abstract_inverted_index":{"OBJECTIVES:":[0],"Antibodies":[1],"to":[2,42,54,64,116],"infliximab":[3,229],"(ATIs)":[4],"have":[5],"been":[6],"associated":[7,265],"with":[8,19,128,193,197,266,282],"a":[9,44,129,141,159,232,267],"risk":[10,49,143,161,236,270],"of":[11,17,38,47,50,62,84,102,132,136,144,164,203,262,271],"infusion":[12,51,167,181,249,273],"reactions":[13,52,182,206,250],"in":[14,146,191,234,280],"some":[15],"studies":[16,81,94,123,139],"patients":[18,192,198,215,281],"inflammatory":[20,283],"bowel":[21,284],"disease.":[22,285],"However,":[23],"many":[24],"factors,":[25],"such":[26],"as":[27],"immunomodulators":[28,63,226,287],"and":[29,58,88,179,213,248],"dosing":[30],"schedule,":[31],"may":[32],"influence":[33],"this":[34,39,65,289],"association.":[35],"The":[36,152,201,260],"aim":[37],"article":[40],"was":[41,77,107,114,158,207],"provide":[43],"pooled":[45,99,130],"estimate":[46],"the":[48,60,125,137],"according":[53],"patients'":[55],"ATI":[56,238],"status":[57],"analyze":[59],"relationship":[61],"risk.":[66,290],"DESIGN:":[67],"Public":[68],"databases":[69],"were":[70,98],"searched":[71],"for":[72,79,100,109,118,237],"eligible":[73],"studies.":[74],"Quality":[75],"assessment":[76],"undertaken":[78],"all":[80,110],"using":[82],"Grading":[83],"Recommendations":[85],"Assessment,":[86],"Development":[87],"Evaluation":[89],"criteria.":[90],"Raw":[91],"data":[92,154],"from":[93],"meeting":[95],"inclusion":[96,126],"criteria":[97],"meta-analysis":[101],"effect":[103],"estimates.":[104],"Sensitivity":[105],"analysis":[106],"performed":[108,115],"outcomes.":[111],"Funnel":[112],"plot":[113],"assess":[117],"publication":[119],"bias.":[120],"RESULTS:":[121],"Eight":[122],"met":[124],"criteria,":[127],"total":[131],"1351":[133],"subjects.":[134],"Seven":[135],"8":[138],"had":[140,231],"high":[142],"bias":[145],"at":[147],"least":[148],"1":[149],"quality":[150],"domain.":[151],"cumulative":[153],"indicated":[155],"that":[156],"there":[157],"higher":[160,269],"ratio":[162],"(RR)":[163],"any":[165],"acute":[166,272],"reaction":[168],"(RR":[169,183,216,240,251],"2.4;":[170],"95%":[171,185,218,242,253],"confidence":[172],"interval":[173],"[CI]":[174],"1.5-3.8,":[175],"P":[176,188,221,245,256],"<":[177,257],"0.001)":[178],"severe":[180],"5.8,":[184],"CI":[186,219,243,254],"1.7-19,":[187],"=":[189,222,246],"0.004)":[190],"ATIs":[194,263],"when":[195],"compared":[196],"without":[199],"ATIs.":[200],"RR":[202],"delayed":[204,277],"hypersensitivity":[205,278],"not":[208,276],"significantly":[209,268],"different":[210],"between":[211],"ATI+":[212],"ATI-":[214],"2.8,":[217],"0.2-33,":[220],"0.4).":[223],"Patients":[224],"prescribed":[225],"during":[227],"maintenance":[228],"therapy":[230],"reduction":[233],"their":[235],"development":[239],"0.6,":[241,252],"0.4-0.9,":[244],"0.02)":[247],"0.4-0.8,":[255],"0.001).":[258],"CONCLUSIONS:":[259],"presence":[261],"is":[264],"reactions,":[274,279],"but":[275],"Concomitant":[286],"reduce":[288]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2051028531","counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":11},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":21},{"year":2020,"cited_by_count":20},{"year":2019,"cited_by_count":15},{"year":2018,"cited_by_count":17},{"year":2017,"cited_by_count":22},{"year":2016,"cited_by_count":19},{"year":2015,"cited_by_count":21},{"year":2014,"cited_by_count":4}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
